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Abstract: Fenfluramine reduces hunger and promotes body weight loss by
increasing central serotonin (5-HT) signaling. More recently, neuropeptides
have been linked to the regulation of feeding behavior, metabolism and body
weight. To examine possible interactions between 5-HT and neuropeptides in
appetite control, fenfluramine (200 nmol/0.5 μl/side) was administered
directly into the hypothalamic paraventricular nuclei (PVN) of male rats.
Bilateral fenfluramine produced significant hypophagia and increased
expression of PVN corticotropin releasing factor (CRF) mRNA and
neuropeptide Y (NPY) mRNA in the arcuate nucleus within the first hour after
drug administration. Fenfluramine’s effects on feeding behavior and mRNA
expression were blocked by PVN injections of a 5-HT1-2 receptor antagonist,
metergoline (15 nmol/0.5 μl/side). These data suggest that 5-HT neurons
targeting hypothalamic paraventricular CRF neurons may participate in an
appetite control circuit for reducing food intake.
Keywords: serotonin, corticotropin-releasing factor, hypothalamus, appetite,
mRNA

Introduction
Drugs used clinically to reduce appetite and body weight
typically manipulate catecholamine and/or serotonin (5-HT) signaling
[3]. One such agent, fenfluramine, which was very effective but is no
longer used clinically [7], is still employed as a research tool to
examine the role of 5-HT neurons in appetite control because it
produces a potent and highly selective stimulation of 5-HT
transmission [10]. Increasing 5-HT synaptic transmission using agents
like fenfluramine decreases appetite and feeding behavior in both
animals and humans [12, 24]. Although the regulation of feeding
behavior by 5-HT is extensively well documented, the mechanisms or
central pathways that mediate this behavior are still poorly
understood.
Numerous 5-HT receptor subtypes are located in the
hypothalamus, a brain region which participates in the control of
feeding and metabolism. The hypothalamic paraventricular nuclei
(PVN) contain moderate to abundant levels of 5-HT2A and 5-HT1B
receptor subtypes, for example, whereas the arcuate nuclei contain
significant quantities of the 5-HT2C receptor [6, 8, 22]. Agonists to
these specific receptor subtypes can suppress food intake while
antagonists block such actions [16, 31, 34]. Given the anatomical
distribution of these receptors, interactions with hypothalamic
neuropeptides known to alter appetite and feeding behavior become a
strong candidate for a mechanism of action of 5-HT-mediated
hypophagia. PVN neurons containing corticotropin releasing factor
(CRF), a neuropeptide that suppresses feeding behavior, receive
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brainstem raphe 5-HT inputs and become activated following systemic
fenfluramine administration [17, 20]. While current approaches to
identify mechanisms of appetite regulation have focused heavily on
neuropeptides as appetite signaling molecules [30], more recent lines
of research have begun to explore for possible interactions between
monoamine (e.g., 5-HT) and neuropeptide neurons in appetite
regulation [14, 28].
Prior studies have demonstrated that systemic fenfluramine in
rats produces a rapid-onset hypophagia (30-60 min) and a
concomitant increase in PVN CRF mRNA levels [4, 18]. To determine
whether this change in CRF mRNA expression is a direct or indirect
action of 5-HT transmission, we administered fenfluramine directly into
the PVN, alone or after administering a 5-HT receptor antagonist, and
measured subsequent changes in food intake and the mRNA
expression of hypothalamic neuropeptides known to influence feeding.

Materials and Methods
Animals
Adult male Sprague-Dawley rats (225-250 g; Harlan,
Indianapolis, IN) were housed singly on a 12 h light/dark cycle and
provided food (Harlan 8604) and water ad libitum. Daily food intake
was measured remotely with a BioDAQ Food Intake Monitor (Research
Diets, New Brunswick, NJ). Feeding bouts measured the number of
times animals physically manipulated the food hopper and removed
food. The duration of a bout was defined as a single episode of feeding
in which no inter-feeding interval exceeded 15 seconds. The Marquette
University Institutional Animal Care and Use Committee approved all
experiments and procedures.

Surgery
Animals were anesthetized with a rodent cocktail consisting of
ketamine/xylazine/acepromazine (77/1.5/1.5 mg/ml/kg; ip) and
placed in a stereotaxic apparatus. Bilateral guide cannulae
(PlasticsOne, Roanoke, VA) were placed 1mm dorsal to the
hypothalamic PVN and secured with an acrylic resin. Stereotaxic
coordinates for the PVN were: anterior/posterior, -1.6mm from
bregma; medial/lateral, ± 0.5mm from midline; dorsal/ventral, 8.4mm from surface of skull [27]. Correct cannulae placements
(cannulae tracks 1 mm dorsal to the PVN) were confirmed at the
conclusion of the experiments on Nissl stained sections.
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In situ hybridization
During the light phase, brains were rapidly removed, cut into 12
μm coronal sections and stored at -80 °C until post-fixed. Standard in
vitro transcription methods were used to generate riboprobes against
CRF (Mayo, Evanston, IL), NPY (Sabol, Bethesda, MD) and POMC
(Wilkinson, Seattle, WA). Sections were hybridized overnight at 55 °C
with each 33P-labeled riboprobe.
After hybridization, slides were stringently washed in 0.5x SSC
for 30 min at 65 °C (CRF, NPY) or 68 °C (POMC) then dipped in Kodak
autoradiographic emulsion NTB (Rochester, NY) and exposed for 11-22
days depending on the specific riboprobe to produce silver grains.

Image analysis
Semi-quantitative analysis of silver grains was conducted using
dark field microscopy (Axioskop-2, Zeiss, Thornwood, NY) and
Axiovision image analysis software (Zeiss, Thornwood, NY). Optical
transmission (OT) was determined from the integration of scattered
light captured with a 5x objective and analyzed for intensity of region
of interest and total area of reflected light. Background values were
subtracted from all measurements.

Radioimmunoassay
Trunk blood, following rapid decapitation, was collected within
the first 6 hours of the dark phase in Experiment 1, whereas blood was
collected just after lights off in Experiment 2. Corticosterone levels
were quantified using a commercial kit (MP Biomedicals, Solon, OH).

Statistical analysis
Data are presented as means ± standard errors of the mean,
and were analyzed statistically by analysis of variance (with repeated
measures when appropriate). When necessary, centering data on their
mean values or natural log transforms were performed prior to
analysis. Fisher’s analysis was used for all post-hoc group comparison.
Statistical analyses were performed using StatView (SAS Institute,
Cary, NC).
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Experiment 1 – Time course of fenfluramine-induced
responses
One week after surgery, animals (n=94 total; n=8-10/group)
received bilateral injections of dl-fenfluramine (Sigma, St. Louis, MO;
200 nmol/0.5 μl/side) or sterile saline (0.5 μl/side) at the dorsal
borders of the paraventricular nuclei. This volume and dose of dlfenfluramine administered into the PVN effectively inhibited
norepinephrine-induced feeding [35].
All injections were administered during the light period 2 hours
prior to dark and in awake animals but measures of food intake and
tissue collection occurred at 1, 2, 4, 8, and 24 hours post-injection. In
a parallel group of animals, brains and trunk blood were collected
following rapid decapitation 1, 2, or 4 hours after injections. These
animals had no further access to food from the time of drug injection.

Experiment 2 – Blocking fenfluramine action in the PVN
One week after surgery, animals (n=32 total; n=7/group)
received two bilateral injections of fenfluramine, metergoline, or
vehicle at the dorsal borders of the paraventricular nuclei. Rats initially
received an injection of the 5-HT1-2 receptor antagonist, metergoline
(Sigma, St. Louis, MO) (15 nmol/0.5 μl/side) or vehicle (1% L-(+)tartaric acid, 0.5 μl/side) followed by either dl-fenfluramine (200
nmol/0.5 μl/side; Sigma St. Louis, MO) or vehicle (sterile saline, 0.5
μl/side). Food was removed two hours prior to drug administration.
Drugs were administered just prior to the onset of dark followed by the
immediate return of food.

Results
Experiment 1 – Time course of fenfluramine-induced
responses
PVN fenfluramine injections produced a rapid hypophagic
response, with significant main effects for both treatment and time
(repeated measures ANOVA). Food intake reduction was evident up to
2 hrs post-injection (fig. 1).

Neuroscience Letters, Vol. 498, No. 3 (July 2011): pg. 213-217. DOI. This article is © Elsevier and permission has been
granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be
further copied/distributed or hosted elsewhere without the express permission from Elsevier.

5

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Fig 1

Time course of food intake following an acute injection of fenfluramine into the
hypothalamic PVN. Feeding was suppressed 2 hours immediately after drug
administration (ANOVA with repeated measures, p<0.02 treatment; p<0.0001 time).
Black bars = fenfluramine (200 nmol/0.5 μl/side); white bars = vehicle. n = 810/group

We measured mRNA expression for several neuropeptides
known to be involved in feeding at one, two, and four hours after drug
injection. PVN fenfluramine injections significantly increased CRF
mRNA expression (fig. 2; ANOVA, p<0.05 for treatment) at 1 hour, but
not 2 or 4 hrs post-injection (p<0.03). Fenfluramine-induced increases
in CRF mRNA were not accompanied by changes in plasma
corticosterone concentrations (fig. 3).
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Fig 2

Dark field analysis of silver grains expressed in unit-less values of optical
transmission (OT). Top, CRF mRNA levels (ANOVA, p<0.05 treatment); bottom, NPY
mRNA levels (ANOVA, p<0.05 treatment) following an acute PVN injection of
fenfluramine (200 nmol/0.5 μl/side). Black bars = fenfluramine; white bars = vehicle;
* = p<0.03 (Fisher’s test), n = 4-5/group.
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Fig 3

Plasma corticosterone levels following fenfluramine administration. No
significant effects were noted in corticosterone levels after A) PVN fenfluramine
administration (200 nmol/0.5 μl/side; black bars = fenfluramine; white bars = vehicle)
or B) following metergoline (MET; 15 nmol/0.5 μl/side) and/or fenfluramine (FEN)
administration compared to vehicle (VEH). n = 4-5/group.

PVN fenfluramine injections also significantly increased NPY
mRNA expression in the arcuate nuclei (fig. 2; ANOVA, p<0.05
treatment effect), although post-hoc testing did not reveal specific
differences at specific time points.

Experiment 2 – Blocking fenfluramine action in the PVN
Central fenfluramine administration in rats receiving no
metergoline produced significant hypophagia at one hour after drug
administration (Fig. 4; ANOVA, p<0.03; post-hoc, p<0.04).
Metergoline did not alter feeding significantly from controls. However,
metergoline administered into the PVN just prior to fenfluramine
reversed the hypophagia by reducing the number of feeding bouts
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(without effects on meal size) within the first hour (fig. 4; ANOVA,
p<0.02; post-hoc, p<0.01).

Fig 4

Levels of food intake and feeding bouts following drug administration.
Metergoline (MET; 15 nmol/0.5 μl/side) or vehicle (VEH) was administered into the
PVN just prior to the PVN injection of fenfluramine (FEN; 200 nmol/0.5 μl/side) or
vehicle. A) Food intake (ANOVA, p<0.03, treatment effect) or B) feeding bouts
(ANOVA, p < 0.02; treatment effect) were measured 1 hour after drug administration.
* = p < 0.04 (Fisher’s test); n = 4-5/group.

As in experiment 1, fenfluramine significantly altered PVN CRF
mRNA expression at one hour post-injection (fig. 5a; ANOVA, p<0.02).
Moreover, post-hoc analysis revealed that CRF mRNA levels in
vehicle/fenfluramine-treated rats were significantly elevated over all
other treatment groups (post-hoc, p<0.03). Metergoline alone did not
alter CRF mRNA expression compared to control values, but blocked
fenfluramine-induced stimulation of PVN CRF mRNA levels. Moreover,
we found no change in CRF mRNA levels in animals treated with
fenfluramine with misplaced cannulae compared to controls (fig. 5a;
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miss). These treatments produced no alterations in serum
corticosterone concentrations (figure 3). NPY mRNA expression in the
hypothalamic arcuate nuclei was significantly increased by
fenfluramine treatment; the effect was also blocked by pre-treatment
with metergoline (fig. 5b; ANOVA, p<0.02 for treatment; post-hoc
p<0.03). In contrast, PVN injections of any combination of
fenfluramine or metergoline did not modify arcuate nuclei POMC mRNA
expression (fig. 5c).

Fig 5

Hypothalamic neuropeptide mRNA levels following drug administration. Dark
field analysis of silver grains expressed as levels of optical transmission (OT) of A)
CRF mRNA in the PVN (ANOVA, main treatment effect p<0.02), B) NPY mRNA in the
arcuate nuclei (ANOVA, main treatment effect p<0.02) and C) POMC mRNA in the
arcuate nuclei 1 hour after an acute injection of fenfluramine (FEN; 200 nmol/0.5
μl/side) and/or metergoline (MET; 15 nmol/0.5 μl/side). Miss = animals treated with
fenfluramine but with incorrect cannulae placement. VEH = vehicle. * = p<0.03
(Fisher’s test); n = 4-5/group.
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Discussion
Systemic administration of fenfluramine, a 5-HT releaser and
reuptake inhibitor, not only decreases feeding behavior [5] but also
increases both c-Fos protein and corticotropin releasing factor (CRF)
mRNA expression in the hypothalamic medial dorsal paraventricular
nuclei [4, 17, 18]. The effects of intraventricular administration of 5HT on feeding are blocked with CRF antibodies. These findings suggest
CRF to be a downstream target that contributes to the anorexic
response of 5-HT [19]. Serotonergic projections from brainstem raphe
nuclei are found in abundance in the medial parvocellular
paraventricular nuclei (PVN) where CRF neurons are concentrated [20,
29, 32] and are known to decrease appetite. Collectively, these studies
suggest the hypothalamic PVN as an important site of serotonergic
regulation of feeding behavior.
Injecting fenfluramine into the PVN reduces overall food intake
by reducing the number of feeding bouts at the onset of darkness
when food intake levels peak. This hypophagia occurs within the first
hours after drug administration and without subsequent rebound
feeding. Similar studies have shown identical responses within subsets
of this time frame [19, 23, 36].
To begin identifying central neurons that respond to
fenfluramine, we examined neuropeptide Y (NPY) and proopiomelanocortin (POMC) in the arcuate nuclei, and CRF, which is
abundantly expressed in PVN neurons. As with systemic fenfluramine
[4, 15], CRF mRNA levels were elevated two hours after fenfluramine
injections into the PVN. Evidence that intraventricular CRF significantly
reduces food intake and CRF-overexpressing mice exhibit diminished
hyperphagia following an overnight fast support a role for CRF
signaling in the regulation of feeding behavior [1, 33]. Although PVN
CRF regulates hypothalamic-pituitary-adrenal axis (HPA) function, the
increase in CRF mRNA expression levels in the current studies was not
accompanied by differences in plasma corticosterone levels, perhaps
suggesting that any effects of increased PVN CRF neuronal activity
were either local or downstream. PVN CRF projections to the nucleus
tractus solitarius may account for, in part, the effects on feeding
without activation of the HPA axis [2]. Moreover, the lack of
measurable corticosterone differences between treatment groups may
also reflect the time of day blood was sampled. We conducted studies
around dark onset to observe fenfluramine effects when rats normally
eat their largest meal. This time of day plasma corticosterone levels
are normally at peak diurnal concentrations with diminished
responsivity to HPA stimulation [9].
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In contrast to PVN delivery of fenfluramine, systemic
administration of the drug produces rapid anorexia, increased PVN CRF
mRNA and a reduction in NPY mRNA expression [4, 26]. The
combination of CRF stimulation and NPY inhibition may reflect
independent drug actions at the paraventricular and arcuate nuclei,
respectively. Conversely, fenfluramine administration into the PVN
may indirectly initiate reflexive responses of appetite-stimulating
signals such as NPY to counter the increasing anorexic drive produced
by CRF. Within the PVN, both 5-HT1B and 5-HT2A receptor
immunoreactivity can be found co-localized with CRF neurons, thus
suggesting possible pathways of 5-HT induced anorexia [8, 22]. A
more recent study demonstrates that antagonism of 5-HT2C receptors
in the PVN can block systemic fenfluramine stimulation of CRF mRNA
[15]. The mechanisms by which PVN CRF stimulation could regulate
arcuate NPY neurons are not presently known, though projections from
the PVN to the arcuate have been described [21]. In the arcuate,
inhibitory 5-HT1B receptors are found to be localized on NPY neurons
[14], allowing the possibility of direct inhibition of arcuate NPY neurons
by systemic fenfluramine.
The present data support the notion that fenfluramine could
induce its anorectic action via a 5-HT receptor-mediated effect on CRF
neurons in the PVN. Furthermore, systemic administration of
fenfluramine or specific 5-HT1B, 5-HT2A, 5-HT2C receptor agonists
suppress food intake while selective or semi-selective antagonists
block such actions [11, 13, 25, 34]. Thus, we examined selective
serotonin receptor subtypes within the PVN. However, since available
data suggest 5-HT-mediated suppression of feeding may occur via
multiple 5-HT receptor subtypes, we chose metergoline, which blocks
both 5-HT1 and 5-HT2 receptors, for study. Indeed, studies that have
employed drugs that are highly-selective for a specific 5-HT receptor
subtype may be overlooking the possibility that the food intake
suppression produced by a drug like fenfluramine may depend on
stimulating more than a single 5-HT receptor. Additional studies are
needed to pursue whether multiple receptor subtypes are necessary to
sufficiently produce fenfluramine’s effects on behavior and gene
expression. Our observation that metergoline in the PVN effectively
blocks fenfluramine’s actions on feeding behavior is consistent with
studies having utilized systemic drug administration, while also
offering the possibility that fenfluramine may be mediating its
anorectic actions, at least in part, via a direct effect on PVN CRF
neurons.
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Research Highlights
1. Fenfluramine is a useful pharmacological tool to increase serotonin
signaling
2. FEN injected directly into the PVN suppresses feeding and increases
CRF mRNA
3. Prior metergoline treatment blocks FEN effects on feeding and mRNA
expression
4. 5-HT - CRF interactions in the PVN may be a useful therapeutic target
for weight loss
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corticotropin releasing factor

NPY

neuropeptide Y

PVN

paraventricular nuclei

POMC pro-opiomelanocortin
OT

optical transmission
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